Javascript must be enabled to continue!
Bridging the evidence gap in gender‐affirming care: urgent research needs
View through CrossRef
Gender‐affirming care has emerged as a critical component of healthcare, addressing the specific medical and psychosocial needs of transgender and non‐binary individuals. In this review article, we address what we see as the most pressing evidence gaps in the gender health literature: long‐term effects of pubertal blockers and gender‐affirming hormone therapy and the lack of standardised outcome measures of gender‐affirming care. Substantial uncertainties persist regarding long‐term effects of hormone therapy and the implications of gender‐affirming therapy on cancer risk. Though there is some uncertainty about the long‐term effects of gender‐affirming medical therapy, providers must also consider the potential negative consequences of prolonging a dysphoric experience. Additionally, there is a dearth of validated measures for patient‐reported outcomes and a lack of standardisation in the reporting of data that is detrimental to the progress of understanding the impacts of gender‐affirming care.
Title: Bridging the evidence gap in gender‐affirming care: urgent research needs
Description:
Gender‐affirming care has emerged as a critical component of healthcare, addressing the specific medical and psychosocial needs of transgender and non‐binary individuals.
In this review article, we address what we see as the most pressing evidence gaps in the gender health literature: long‐term effects of pubertal blockers and gender‐affirming hormone therapy and the lack of standardised outcome measures of gender‐affirming care.
Substantial uncertainties persist regarding long‐term effects of hormone therapy and the implications of gender‐affirming therapy on cancer risk.
Though there is some uncertainty about the long‐term effects of gender‐affirming medical therapy, providers must also consider the potential negative consequences of prolonging a dysphoric experience.
Additionally, there is a dearth of validated measures for patient‐reported outcomes and a lack of standardisation in the reporting of data that is detrimental to the progress of understanding the impacts of gender‐affirming care.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
Organisatie van geestelijke gezondheidszorg voor mensen met een ernstige en persisterende mentale aandoening
Organisatie van geestelijke gezondheidszorg voor mensen met een ernstige en persisterende mentale aandoening
1 INTRODUCTION AND RESEARCH QUESTIONS 5 -- 2 GENERAL BACKGROUND: DEFINITIONS AND SCOPE OF THE STUDY 7 -- 2.1 CHRONIC AND COMPLEX MENTAL DISORDERS: DEFINITIONS AND SCOPE OF THE -- S...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Gender identity development in autistic individuals: An interview study
Gender identity development in autistic individuals: An interview study
Autistic individuals report more gender-related questions and gender incongruence compared to non-autistic peers. However, research on gender identity in autistic individuals lacks...
Elmer Belt, Harry Benjamin, and the Birth of Gender-Affirming Surgery in the United States
Elmer Belt, Harry Benjamin, and the Birth of Gender-Affirming Surgery in the United States
Abstract
Introduction
Gender Affirming Surgery (GAS) originated in early 20th century Europe and innovators there established some of the first surgical and social principles of ...
149 Medical, Gender Dysphoria, and Quality-of-Life Benefits of Pre-Vaginoplasty Bilateral Orchiectomy
149 Medical, Gender Dysphoria, and Quality-of-Life Benefits of Pre-Vaginoplasty Bilateral Orchiectomy
ABSTRACT
Introduction
Gender-affirming bilateral orchiectomy (GABO) can be offered to patients in 3 ways: as a stand-alone proce...
Towards more goal-oriented care through care coordination and care planning.
Towards more goal-oriented care through care coordination and care planning.
The increasing aging of our society is putting increasing pressure on the current organization of care and support. This moved the Flemish government to a thorough reform of primar...

